[Federal Register: September 13, 1999 (Volume 64, Number 176)]
[Notices]               
[Page 49510-49511]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr13se99-114]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 22,

[[Page 49511]]

1999, Novartis Pharmaceutical Corporation, 59 Route 10, East Hanover, 
New Jersey 07926, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
methylphenidate (1724), a basic class of controlled substance listed in 
Schedule II.
    The firm plans to manufacture finished product for distribution to 
its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than November 12, 1999.

    Dated: August 31, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcemenet Administration.
[FR Doc. 99-23670 Filed 9-10-99; 8:45 am]
BILLING CODE 4410-09-M